Free Trial
NASDAQ:KRRO

Korro Bio (KRRO) Stock Price, News & Analysis

Korro Bio logo
$57.50
-3.35 (-5.51%)
(As of 10/31/2024 ET)

About Korro Bio Stock (NASDAQ:KRRO)

Key Stats

Today's Range
$55.22
$61.14
50-Day Range
$31.30
$80.04
52-Week Range
$9.76
$98.00
Volume
122,282 shs
Average Volume
65,863 shs
Market Capitalization
$533.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$142.17
Consensus Rating
Buy

Company Overview

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Korro Bio Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
52nd Percentile Overall Score

KRRO MarketRank™: 

Korro Bio scored higher than 52% of companies evaluated by MarketBeat, and ranked 598th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Korro Bio has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Korro Bio has only been the subject of 4 research reports in the past 90 days.

  • Read more about Korro Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Korro Bio are expected to decrease in the coming year, from ($10.09) to ($10.87) per share.

  • Price to Book Value per Share Ratio

    Korro Bio has a P/B Ratio of 2.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Korro Bio's valuation and earnings.
  • Percentage of Shares Shorted

    4.63% of the float of Korro Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Korro Bio has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Korro Bio has recently increased by 23.07%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Korro Bio does not currently pay a dividend.

  • Dividend Growth

    Korro Bio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.63% of the float of Korro Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Korro Bio has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Korro Bio has recently increased by 23.07%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Korro Bio has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Korro Bio this week, compared to 1 article on an average week.
  • Search Interest

    4 people have searched for KRRO on MarketBeat in the last 30 days.
  • MarketBeat Follows

    4 people have added Korro Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Korro Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $799,504.00 in company stock.

  • Percentage Held by Insiders

    16.80% of the stock of Korro Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 13.18% of the stock of Korro Bio is held by institutions.

  • Read more about Korro Bio's insider trading history.
Receive KRRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Korro Bio and its competitors with MarketBeat's FREE daily newsletter.

KRRO Stock News Headlines

Korro Bio (NASDAQ:KRRO) Research Coverage Started at Raymond James
Banking failure dead ahead
If you missed it, my emergency election broadcast is now available - but will be removed soon
Korro Bio initiated with a Strong Buy at Raymond James
Korro Bio price target raised to $105 from $95 at RBC Capital
See More Headlines

KRRO Stock Analysis - Frequently Asked Questions

Korro Bio's stock was trading at $47.93 on January 1st, 2024. Since then, KRRO shares have increased by 20.0% and is now trading at $57.50.
View the best growth stocks for 2024 here
.

Korro Bio, Inc. (NASDAQ:KRRO) posted its quarterly earnings results on Tuesday, August, 13th. The company reported ($2.43) EPS for the quarter, missing the consensus estimate of ($2.39) by $0.04.

Shares of KRRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Korro Bio investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
8/13/2024
Today
10/31/2024
Next Earnings (Estimated)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KRRO
Previous Symbol
NASDAQ:KRRO
Fax
N/A
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$142.17
High Stock Price Target
$180.00
Low Stock Price Target
$105.00
Potential Upside/Downside
+141.7%
Consensus Rating
Buy
Rating Score (0-4)
3.17
Research Coverage
6 Analysts

Profitability

Net Income
$-81,170,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$14.07 million
Book Value
$21.19 per share

Miscellaneous

Free Float
8,797,000
Market Cap
$545.35 million
Optionable
No Data
Beta
2.15
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:KRRO) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners